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Abstract
The synthesis of inactive enzyme precursors, also known as ‘‘zymogens,’’ serves as a mechanism for regulating the execution
of selected catalytic activities in a desirable time and/or site. Zymogens are usually activated by proteolytic cleavage. Many
viruses encode proteases that execute key proteolytic steps of the viral life cycle. Here, we describe a proof of concept for a
therapeutic approach to fighting viral infections through eradication of virally infected cells exclusively, thus limiting virus
production and spread. Using the hepatitis C virus (HCV) as a model, we designed two HCV NS3 protease-activated
‘‘zymogenized’’ chimeric toxins (which we denote ‘‘zymoxins’’). In these recombinant constructs, the bacterial and plant
toxins diphtheria toxin A (DTA) and Ricin A chain (RTA), respectively, were fused to rationally designed inhibitor peptides/
domains via an HCV NS3 protease-cleavable linker. The above toxins were then fused to the binding and translocation
domains of Pseudomonas exotoxin A in order to enable translocation into the mammalian cells cytoplasm. We show that
these toxins exhibit NS3 cleavage dependent increase in enzymatic activity upon NS3 protease cleavage in vitro. Moreover,
a higher level of cytotoxicity was observed when zymoxins were applied to NS3 expressing cells or to HCV infected cells,
demonstrating a potential therapeutic window. The increase in toxin activity correlated with NS3 protease activity in the
treated cells, thus the therapeutic window was larger in cells expressing recombinant NS3 than in HCV infected cells. This
suggests that the ‘‘zymoxin’’ approach may be most appropriate for application to life-threatening acute infections where
much higher levels of the activating protease would be expected.
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Introduction
The term ‘‘zymogen’’ refers to an inactive enzyme precursor
that is converted to its active form following a biochemical
modification, usually proteolytic processing. Among the known
and important groups of enzymes that are activated in such a way
are the cysteine aspartic acid proteases (caspases) which play an
essential role at various stages of the apoptotic process [1]; secreted
digestive enzymes like pepsin and trypsin [2,3] and blood
coagulating factors [4].
Previously, Alexander Varshavsky suggested the construction of
a new kind of toxins referred as ‘‘sitoxins’’, a concept that
artificially combines several functional protein domains to produce
a therapeutically effective molecule. More specifically, a sitoxin is
comprised of an effector domain, a domain bearing an
intracellular signaling moiety; and a polypeptidic sequence located
between the effector domain and the domain bearing the
intracellular signaling moiety which specifies a cleavage site for a
predetermined protease. Following the introduction of the sitoxin
into the target cell (that expresses the specific protease), cleavage
by the protease separates the effector domain of the sitoxin from
the intracellular signaling moiety, resulting either in a longer-lived
(and therefore more toxic) effector domain or in an effector
domain that moves from a cellular compartment where the
domain is nontoxic to a cellular compartment where the domain is
able to exert its toxic effect [5]. This strategy was previously
applied by Falnes et al., who described the construction of
diphtheria toxin based sitoxins that contain a signal for N-end-
rule-mediated degradation just upstream of a cleavage site for the
protease from HIV type 1. In-vitro cleavage by the viral protease
substantially increased the ability of the toxins to inhibit cellular
protein synthesis; however, the toxins were unable to selectively
eradicate HIV-1-infected cells, apparently due to low cytosolic
HIV-1 protease activity [6].
Pseudomonas exotoxin A (PE) is a three-domain bacterial toxin
that kills mammalian cells by gaining entry to the cytosol and
inactivating protein synthesis. PE is composed of 3 major domains
and 1 minor domain; domain 1a (a.a.1–252) is the cell-binding
domain. Domain 2 (a.a.253–364) is the translocation domain that
enables PE to reach the cytosol. Domain 3 (a.a.395–613) is the
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causes cell death. The pathway of toxin entry includes 1) binding
to a surface receptor - PE binds and enters mammalian cells via
binding of domain 1 to the alpha 2-macroglobulin receptor/low
density lipoprotein receptor-related protein (LRP) which is
ubiquitously expressed in most tissues and cell types [7]. 2).
Internalization via coated pits to endosomes. 3) Proteolytic
cleavage between Arg-279 and Gly-280 within domain 2 and
reduction of disulfide bonds [8]. This proteolytic cleavage is
mediated by the cellular protease furin, generates the active C-
terminal fragment (residues 280–613). 4) Finally, the enzymatically
active C-terminal fragment is translocated by retrograde transport
through the Golgi apparatus to the endoplasmic reticulum and
from there to the cytosol [9,10,11]. Once in the cytosol, this
fragment inhibits protein synthesis by ADP ribosylating elongation
factor 2 [12,13].
Diphtheria toxin (DT), produced by Corynebacterium diphtheriae,
kills mammalian cells in a mechanism similar to that of PE,
namely, by gaining entry to the cytosol and inactivating protein
synthesis by ADP ribosylating elongation factor 2. Diphtheria
toxin is composed of three structural and functional domains: the
amino terminal catalytic (C) domain (also referred to as ‘‘DTA’’),
the translocation domain (T) and the carboxy-terminal receptor
binding (R) domain [14]. DT is cleaved at the surface of sensitive
eukaryotic cells by the enzyme furin, and following receptor (the
heparin binding epidermal growth factor-like precursor) binding,
the di-chain protein that is linked by a single disulfide bond is
internalized into clathrin coated pits and reaches the lumen of a
developing endosome. Upon acidification, the T domain facilitates
the translocation of the catalytic domain directly across the
endosomal membrane and into the host cell cytoplasm [15,16].
Ricinus communis ricin toxin is a ribosome-inactivating protein
(RIP) which irreversibly damages ribosomes by removal of a single
adenine residue (‘‘depurination’’) from a GAGA sequence in a
universally conserved loop at the top of a stem in 28S rRNA, the
so-called ‘‘sarcin/ricin loop’’ (SRL). The toxin consists of two
chains linked together by a disulfide bond, one chain of
approximately 30 KDa with N-glycosidase enzymatic activity
(the A chain), and one of approximately 35 KDa with lectin
properties which binds carbohydrate ligands on target cell surface
(the B chain) [17]. Cell-bound ricin is taken up by endocytosis.
From here, most of the toxin molecules are recycled back to the
cell surface or transported to the lysosomes and degraded. Only a
small fraction is eventually translocated by retrograde transport to
the trans-Golgi network, backward through the Golgi apparatus to
the endoplasmic reticulum and from there to the cytosol [18].
HCV is a small, enveloped RNA virus belonging to the
Hepacivirus genus of the Flaviviridae family, which has been
recognized as a major cause of chronic liver disease and affects
approximately 200 million people worldwide at the present time.
Persistent infection is associated with the development of chronic
hepatitis, hepatic steatosis, cirrhosis, and hepatocellular carcino-
ma. A protective vaccine for HCV is not yet available and even the
most recent combination of pegylated a-interferon and ribavirin
fails to eliminate infection in nearly 50% of those infected [19].
The HCV genome encodes one large open reading frame that is
translated as a polyprotein and proteolytically processed to yield the
viral structural and nonstructural (NS) proteins. The envelope
glycoproteinsE1andE2aswellasthecore proteinarethestructural
proteins, which form the viral particle. The non-structural proteins
include the p7 ion channel, the NS2-3 protease, the NS3 serine
protease/RNA helicase and its co-factor NS4A , the NS4B and
NS5A proteins and the NS5B RNA-dependent RNA polymerase
(RdRp) [20,21]. Two virally encoded proteases participate in
polyprotein processing, the NS2-3 autoprotease (which cleaves in cis
at the NS2-3 junction) and the NS3-4A serine protease (also
commonly referred to as NS3 protease, which cleaves at four
downstream NS protein junctions). NS3 is an extensively studied
HCV protein that possesses multiple enzymatic activities that are
essential for HCV replication. The N-terminus, in complex with its
co-factor NS4A, primarily functions as a serine protease, which
cleaves the viral polyprotein precursor downstream to NS3. The
remaining 2/3 of the protein has a helicase and NTPase activities,
both of which are essential for HCV replication [22].
For a long time, the only approaches to study the full HCV life
cycle were experimental infection of chimpanzees, observation of
infected patients and comparison with other viruses, members of the
Flaviviridae family. Recently, different systems enabling the replica-
tion and growth of HCV in cell culture (HCVcc) were developed.
These advances resulted in the establishment of currently used
models to study hepatitis C virus in which recombinant infectious
HCV particles (of genotype 2a strain JFH1 and other chimeric
viruses generated in the JFH1 background) could be produced in
Huh7 hepatoma-derived cell lines that are permissive for HCV
replication. HCVcc systems render all steps of the HCV life cycle,
including entry and release of viral particles, amenable to systematic
analysis. [23,24,25,26,27,28,29,30,31].
For the purpose of development of a proof of concept for a
potential new anti-viral agents that will specifically eradicate virally
infected cells (thus limiting virus production and spread), we
designed two chimeric toxins which activation is mediated by
HCV-NS3 protease cleavage. These chimeric toxins are based on
a fusion between the binding and translocation domains of
Pseudomonas exotoxin A (serving as a vehicle for translocation into
the cytoplasm of target cells) and NS3-activable modified catalytic
domains of the bacterial or the plant toxins diphtheria toxin (DTA)
or ricin toxin (RTA), respectively. In these constructs, which we
denote ‘‘zymoxins’’ (zymogenized toxins), a rationally designed
inhibitory peptide/domain is fused to the C terminus of the
constitutively active toxins. The inhibitory domain is preceded by
the NS3-sensitive NS5A/B junction sequence which cleavage by
the viral protease liberates the toxin from the inhibitory moiety.
These toxins exhibit considerable level of NS3 protease-dependent
activation as was detected by in-vitro enzymatic assays, as well as
when applied to NS3 expressing model cells (expressing cytosolic
or membrane bound NS3). When tested on HCV infected cells, a
less dramatic, but still significant enhancement of cytotoxicity was
observed, suggesting that eradication of viral protease expressing
cells at specific ranges of toxin concentrations can be achieved.
Results
Establishment of NS3 protease-expressing model cell
system
For the purpose of establishing a model cell line expressing the
HCV NS3 protease, we constructed a fusion protein between the
previously described NS4A-NS3 (also known as single-chain NS3;
scNS3) [32] - a single chain construct where a short synthetic
peptide encompassing residues 21–34 of NS4A (of the 1b HCV
genotype) was linked to the N terminus of the NS3 protease
domain [33,34,35], and enhanced green fluorescence protein
(EGFP). This format was chosen based on our previous
unpublished finding that the expression level of scNS3 in
mammalian cells is greatly enhanced upon fusion of efficiently-
expressed proteins (such as EGFP) to its N terminus. In addition,
another construct was made, comprising a fusion of EGFP and the
full length NS3 (protease/RNA helicase) followed by full length
NS4A (of the 1a HCV genotype) [36]. As opposed to EGFP-
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nucleocytoplasmic protein with relatively low affinity to mem-
branes, the EGFP- full length NS3 (which strongly interacts with
the full length NS4A following auto-cleavage) is expected to be
associated with intracellular membranes when expressed in
mammalian cells, more precisely mimicking the intracellular
localization of this complex in HCV infected cells. The reason for
that is that the hydrophobic amino terminal domain of the NS4A
directs the NS3-NS4A complex to the ER membrane or an ER-
like modified compartment [20,37,38,39,40].
Since signs of cell toxicity were observed following prolonged
constitutive expression of EGFP-scNS3 and EGFP-full NS3-4A in
HEK293 cells, a TET-ON inducible system for NS3 expression
was established. In this system, based on T-REx
TM 293 Cell Line
(Invitrogen), expression of EGFP-scNS3 or EGFP full NS3-4A
(also later referred to as ‘‘scNS3’’ and ‘‘full NS3-4A’’, respectively)
is induced by addition of tetracycline (Tet) to the growth medium.
In order to monitor specific NS3 proteolytic activity in Tet
induced cells, we constructed a substrate-encoding plasmid that
encodes for a modification of our previously described polypeptide
which serves as a substrate for proteolysis by the NS3 protease
[33]. This plasmid, denoted pCMV/MBP-EGFP-NS5AB-CBD,
encodes for a fusion of maltose binding protein (MBP), enhanced
green fluorescence protein (EGFP), the 10 amino acid minimal
NS3 cleavage sequence (P6-P49) from HCV NS5A/B site derived
from HCV genotype 1b/1a ( for both 1b and 1a genotypes this
sequence is identical) [41] and cellulose binding domain (CBD). As
shown in Fig. 1, addition of Tet to selected stable clones of the
inducible system results in EGFP-scNS3 and EGFP- full NS3-4A
expression, as assayed by fluorescence confocal microscopy (Fig. 1B
and 1C, respectively) and immunoblotting (Fig. 1E, lower panel).
Regarding the intracellular localization of the proteases, EGFP-full
NS3-4A was only partially colocalized with calnexin (ER) in these
cells, but apparently was absent from the nucleus and has less
diffuse distribution pattern in comparison to the nucleocytoplamic
EGFP-scNS3, as was expected. A strong colocalization, however,
was observed between EGFP-full NS3-4A and a chimeric
fluorescent protein which was fused to the C-terminal ER
membrane anchor of the tyrosine phosphatase PTP1B [42] (data
not shown). Immunoblot analysis also shows efficient cleavage of
MBP-EGFP-NS5AB-CBD (referred to as the ‘‘cleavable sub-
strate’’ (Fig. 1D)) in cells transfected with pCMV/MBP-EGFP-
Figure 1. Tetracycline induced expression of active EGFP-scNS3 and EGFP- full NS3-4A in T-Rex 293 cells. Upper panel:
immunofluorescence analysis of inducible NS3 expressing cells: 10
5 cells inducibly expressing EGFP-scNS3 or EGFP-full NS3-4A were seeded on cover-
slips in a 24 well-plate. After 12 hours, the cells were treated with 1mg/ml of tetracycline for 24 hours and then were fixed and permeabilized.
Following immunostaining with rabbit anti-calnexin and Cy3-conjugated goat anti rabbit for ER visualization (red) and nuclei staining by Hoechst
33258 (Blue), slides were examined by confocal fluorescence microscopy. (A). Uninduced cells. (B). Induced scNS3 expressing cells. (C). Induced full
NS3-4A expressing cells. Lower panel: in-vivo substrate cleavage by NS3: cells inducibly expressing EGFP-scNS3 were transfected with 2mg of the
plasmid pCMV/MBP-EGFP-NS5AB-CBD (‘‘cleavable substrate’’- see scheme in D). After 24 hours, cells were treated with 1mg/ml of tetracycline or left
untreated. 24 hours later, cells were lysed and 20mg protein from total cell extract where analyzed by immunoblotting with rabbit anti-EGFP
antibodies (for detection of EGFP-scNS3) and mouse-serum anti-MBP (which is more sensitive than anti-EGFP in detecting the cleavage products of
the substrate) followed by HRP-conjugated secondary antibodies and ECL development (E). Bands corresponding to the full length substrate, cleaved
substrate and EGFP-scNS3 are indicated by arrows. Similar results were obtained also in cells inducibly expressing EGFP-full NS3-A4.
doi:10.1371/journal.pone.0015916.g001
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band, corresponding to the cleavage product, was also detected in
a sample from uninduced cells. This is probably due to some
degree of ‘‘leakiness’’ of the Tet inducible system, allowing a very
low basal transcription of the protease in the absence of externally
added Tet. In support to this assumption, only a single band
corresponding to the full length substrate was detected when
‘‘naı ¨ve’’ HEK293 T-Rex cells were transfected with the substrate
encoding vector (data not shown).
The construction of diphtheria toxin based zymoxin
As can be inferred from toxin-substrate interaction model
previously presented by Jorgensen and colleagues, an intimate
interaction between DTA and its intracellular target elongation
factor 2 is predicted to reside in the C terminal portion of the toxin
[43]. Considering that prediction, we assumed that a fusion of a
bulky polypeptide moiety to the C terminus of DTA may hinder
the toxin-substrate interaction. Furthermore, human alpha-
defensin 1 (HNP1) was found to neutralize toxins of the mono-
ADP-ribosyltransferase family (to which DTA belongs) [44]. To
construct a zymoxin where the catalytic domain of DTA is
inhibited by HNP1, and the inhibition is relieved by NS3 cleavage,
we chose to fuse HNP1 to the C terminus of DTA. The HNP1 was
preceded by the 10 amino acids minimal NS3 cleavage sequence
(P6-P49) from HCV (genotype 1b/1a) NS5A/B site (referred to as
‘‘cleavage site’’) and a flexible linker of 15 amino acids rich in
serine and glycine residues which should allow the HNP1 domain
to ‘‘fold back’’ and interact with its interaction site on DTA. This
construct was then fused in its N terminus to the binding and
translocation domain of Pseudomonas exotoxin A (PE) in order to
enable internalization and trafficking to the cytosol of mammalian
cells (demonstrated previously by Guidi-Rontani [45]), as the
natural binding and translocation domains of the diphtheria toxin,
which are positioned to the C terminus of the W.T toxin, were
substituted by the HNP1 polypeptide. In addition, a 6xHis tag
followed by a KDEL ER retrieval signal were placed at the most C
terminal portion of the construct (‘‘PE-DTA-cleavage site-
defensin’’), for facilitating the toxin purification and as the KDEL
retrieval system is exploited by PE in order to reach the ER lumen
[11], respectively. This 6xHis- KDEL extension was positioned at
the C terminus of all following chimeric constructs, which have
been expressed in E. coli BL21 cells and purified from the
periplasmic fraction as described in ‘materials and methods’. As a
control, an uncleavable chimeric toxin was constructed, in which
the NS3 cleavage site was mutated by substituting P1 cysteine to
arginine and P49 tyrosine to alanine (‘‘PE-DTA-mutated cleavage
site- defensin’’, see scheme in Fig. 2A). Protein sequences of the
zymoxins described above, as well as all the zymoxins used in the
study (that will be described later), can be found in supporting
Text S1.
The enzymatic activity of DTA-based zymoxin is elevated
following NS3 protease cleavage
In order to evaluate the susceptibility of the above constructs to
cleavage by the NS3 protease and to evaluate the influence of such
cleavage on their ADP-ribosylation activity, an in-vitro cleavage
reaction was carried out (by incubating the chimeric toxins with
recombinant MBP-scNS3 fusion produced in E. coli. [32]), followed
by ADP-ribosylation activity assay using wheat germ extract as a
source of elongation factor 2 [46,47]. A schematic representation of
the PE-DTA chimeric toxins, the in-vitro cleavage products and the
ADP-ribosylation assay results are shown in Fig. 2. As shown,
incubation of the toxin ‘‘PE-DTA-cleavage site-defensin’’ with the
recombinant protease resulted in a complete cleavage of the
chimeric toxin that appeared as a lower weight product in
immunoblot assay using anti-PE antibodies (Fig. 2A-right and
upper panel). Moreover, the cleavage led to a considerable increase
in the ADP-ribosylation activity of the toxin (Fig. 2B).
Incontrast,thetoxinwiththemutatedcleavagesitewasresistantto
cleavage by NS3, and no significant increase in its ADP-ribosylation
activity could be detected after incubation with the protease.
Interestingly, the ADP-ribosylation activity of the uncleavable toxin
is higher than the basal activity of the uncleaved-cleavable toxin (but
lower than the cleaved toxin). However, it should be emphasized at
this point that as enzymatic activity and cytotoxicity may be affected
by multiple factors such as translocation efficiency, thermodynamic
stability, intracellular half-life and interaction with substrate (that
might be influenced by even a slight change in the primary sequence
of the toxin), basically the most correct control for each cleavable
toxin is itself when uncleaved.
The cytotoxicity of DTA-based zymoxin is elevated in NS3
expressing cells
In order to evaluate the toxin activation by HCV protease in-vivo,
ourmodel cell lines,inducedoruninducedforNS3 expression,were
treated with ‘‘PE-DTA-cleavage site-defensin’’ or ‘‘PE-DTA-
mutated cleavage site- defensin’’. As shown in Fig. 3., tetracycline
induction for expression of scNS3 and full NS3-4A has led to
considerable activation of the cleavable toxin which presented only
a minor cytotoxic effect against uninduced cells. On the contrary,
no enhancement in cytotoxic activity of the uncleavable toxin was
evident; indicating that induction of NS3 expression does not cause
a general sensitization to DTA based toxins in these cells. In
agreement with the in-vitro ADP-ribosylation assay results, the
uncleavable toxin basal activity was more potent than the basal
activity of the non-cleaved cleavable toxin (uninduced cells treated
with ‘‘PE-DTA-cleavage site-defensin’’).
In this context, it is worth mentioning that another uncleavable
toxin, ‘‘PE-DTA-no cleavage site-defensin’’ in which the whole
NS3 cleavage site was deleted, is also indifferent to the presence of
the protease and it is as potent as the non-cleaved cleavable toxin
(presents only a minor cytotoxic effect against induced or
uninduced NS3 expressing cells) (data not shown). These
observations further suggest that the most correct evaluation of
the therapeutic window a zymoxin may offer is to compare the
cleaved to the un-cleaved zymoxin itself.
The construction of ricin toxin based zymoxin
Since the enzymatic activity of ricin is based on its interaction
with ribosomes, one can assume that interruption of this
interaction will probably reduce its toxicity. In the recent years,
several groups have investigated the nature of the this interaction
and it was found that the conserved C terminus of the ribosome
stalk proteins P1 and P2 interacts with both ricin and Shiga-like
toxin 1 (SLT-1), another type II ribosome-inactivating protein,
and this interaction is required for efficient ribosome binding and
cytotoxicity. Moreover, a synthetic peptide corresponding to the
sequence of the conserved C terminus of P1 and P2 was shown to
inhibit the ribosome-inactivating function of SLT-1 [48,49,50].
Later on, the crystal structure of a similar peptide in complex with
trichosanthin (TCS), a type I ribosome-inactivating protein (RIPs),
was presented [51]. Based on these studies, we have cloned the
coding sequence of the catalytic A chain of ricin (RTA), originated
from Ricinus communis genomic DNA preparation, into a bacterial
expression plasmid. Next, we have constructed a chimeric toxin in
which two repeats of the acidic 16 residue peptide corresponding
to the conserved C terminus of the ribosomal stalk proteins
(EESEESDDDMGFGLFD) were fused to the C terminus of RTA.
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chimera described earlier, in the cleavable toxin (‘‘PE-RTA-
cleavage site-stalk peptide’’) the NS3 protease minimal cleavage
sequence (P6-P49) from genotype 1b/1a NS5A/B junction was
inserted between RTA and the ribosome stalk peptide, while in the
control uncleavable toxin (‘‘PE-RTA- mutated cleavage site-stalk
peptide’’) a mutated cleavage site was positioned at this location.
This construct was then fused in its N terminus to the binding and
translocation domain of PE, as the natural binding and
translocation domain of ricin toxin (RTB) undergoes N-glycosyl-
ation when produced in Ricinus communis, which is necessary for its
lectin activity. By fusing RTA to the bacterially derived binding
and translocation domains of PE, chimeric PE-RTA toxins that
are capable of penetrating into the mammalian cell cytoplasm
(demonstrated previously by Pitcher et al [52]) may be produced in
E. coli by standard methods.
Figure 2. In-vitro cleavage by NS3 and ADP-ribosylation assay of DTA-based zymoxins. (A). Left panel: a schematic representation of the
toxins ‘‘PE-DTA-cleavage site-defensin’’ and ‘‘PE-DTA-mutated cleavage site- defensin’’. Right panel: in-vitro cleavage by NS3: 600ng of each toxin
were incubated with or without 500ng of recombinant MBP-scNS3 fusion in a total volume of 60ml for 1 hour at 37uC. Afterwards, 50ng of each toxin
were subjected to SDS-PAGE and immunoblotting by anti-PE polyclonal antibodies (aPE) followed by HRP-conjugated goat anti rabbit antibody and
ECL development. (B). ADP-ribosylation assay for cleaved and uncleaved toxins: 30ng of each toxin (cleaved and uncleaved) were mixed with wheat
germ extract and [
14C]-NAD and incubated for 40 min at RT. Reactions were terminated by addition of TCA to the reaction mixture which resulted in
total protein precipitation. Level of ADP-ribosylated EF2 was assessed by measuring the radioactivity of the precipitated protein by a scintillation
counter. Results (in CPM) are represented as the mean 6SD of a set of data determined in triplicates (** P-value,0.005).
doi:10.1371/journal.pone.0015916.g002
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following NS3 protease cleavage
In order to assess the susceptibility of the RTA-zbased
constructs to cleavage by NS3 and evaluate the influence of such
cleavage on their ribosome depurination activity, an in-vitro
cleavage reaction was carried out (as described for the diphtheria
toxin chimera) following by ribosome depurination assay using the
‘‘acidic aniline’’ method on ribosomes from reticulocyte lysate
[53,54]. In this method, the phosphodiester bond at the 39 site of
the depurinated adenine in the ricin treated rRNA is cleaved
under treatment with aniline under acidic conditions, and a small
fragment of about 460 nucleotides (‘‘R fragment’’) is released and
can be detected by agarose or acrylamide gel electrophoresis and
staining with ethidium bromide. A schematic representation of the
PE-RTA chimeric toxins, the in-vitro cleavage and the ribosome
depurination assay results are represented in Fig. 4.
As shown, incubation of the toxin ‘‘PE-RTA-cleavage site-stalk
peptide’’ with recombinant NS3 protease resulted in a complete
cleavage of the chimeric toxin that appeared as a lower weight
product (Fig. 4A-right and upper panel). In contrast, the
uncleavable toxin remained indifferent to the presence of the
protease. Moreover, the cleavage has led to an increase in
ribosome depurination activity of the toxin, as inferred from the
appearance of the ‘‘R fragment’’ when ribosomes were treated
with 50 ng/ml of the cleaved toxin. This fragment was
undetectable when ribosomes were treated with the same
concentration of non-cleaved cleavable toxin (cleavable toxin
without incubation with NS3) or with the uncleavable toxin
(Fig. 4B). At higher toxin concentrations and in the presence of
aniline, the R fragment could be detected after treatment with
both the cleaved and the uncleavable toxins. This may result from
the fact that the zymoxin is partially and not totally inhibited by
the C-terminal extension (as can be also inferred from the
cytotoxicity assays shown below).
The cytotoxicity of RTA-based zymoxin is elevated in NS3
expressing cells
In orderto verifytheactivation of the RTA-based toxinsbyHCV
protease in-vivo, the model cell lines, induced or uninduced for NS3
expression, were treated with ‘‘PE-RTA-cleavage site-stalk peptide’’
Figure 3. Viability assay of NS3 expressing cells treated with DTA based zymoxins. T-Rex cells inducibly expressing scNS3 or full NS3-4A
were seeded in 96-well plates (4610
4 cells per well). After 9 hours, cells were treated with 1mg/ml of tetracycline (+TET) or left untreated (NO TET).
2 hours later, cells were incubated for 72 hours with serial dilutions of the toxins ‘‘PE-DTA-cleavage site-defensin’’ or ‘‘PE-DTA-mutated cleavage site-
defensin’’ (presence of tetracycline was kept in the growth media of induced cells). The relative fraction of viable cells was determined using an
enzymatic MTT assay. A representative graph of three independent experiments is shown. Each point represents the mean 6SD of a set of data
determined in triplicates.
doi:10.1371/journal.pone.0015916.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15916Figure 4. In-vitro cleavage by NS3 and ribosome depurination assay of RTA-based zymoxins. (A). Left panel: A schematic representation
of the toxins ‘‘PE-RTA-cleavage site-stalk peptide’’ and ‘‘PE-RTA- mutated cleavage site-stalk peptide’’. Right panel: in-vitro cleavage by NS3: 3000ng of
each toxin were incubated with or without 1000ng of recombinant MBP-scNS3 fusion in a total volume of 60ml for 1 hour at 37uC. Afterwards, 250 ng
of each toxin were subjected to SDS-PAGE and immunoblotting by anti-PE (aPE) polyclonal antibodies. (B). Ribosome depurination assay: A serial
dilution of each toxin (treated or untreated with NS3) was incubated with 10ml of rabbit reticulocyte lysate for 30 minutes at 30uC, after which total
RNA from each mixture was extracted. Half of the RNA was treated with acidic aniline (1M aniline in 2.8 M acetic acid) for 10 minutes at 40uC and the
other half remained untreated. Next, RNA was extracted and analyzed by 3% TBE agarose gel electrophoresis and staining with ethidium bromide.
The position of the ‘‘R fragment’’, which released from rRNA of ricin-treated ribosomes after treatment with aniline, is marked by an arrow.
doi:10.1371/journal.pone.0015916.g004
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Fig. 5., tetracycline induced expression of scNS3 and full NS3-4A
has led to considerable activation of the cleavable toxin, while no
profound enhancement in cytotoxicity of the control uncleavable
toxin was observed. Another construct, in which only the 6xHis-
KDEL extension was fused to the C terminus of RTA, was also
relatively inert to scNS3 protease expression exhibiting only minor
enhancement in cytotoxicity toward Tet-induced scNS3 expressing
cells(IC50valuesof30ng/mlvs.20ng/mlinuninducedandinduced
cells, respectively) (data not shown).
The elevated cytotoxicity of DTA and RTA based
zymoxins corresponds to the level of intracellular NS3
proteolytic activity
The elevated cytotoxic effect that was observed in zymoxins
treated NS3 expressing cells suggests the in-vivo NS3 dependent
activation of the zymoxins. Thus, a direct correlation between the
level of cellular NS3 proteolytic activity and enhancement in
cytotoxicity upon zymoxins treatment is expected. In order to test
this assumption, we took advantage of the partially ‘‘tunable’’
nature of the tetracycline inducible NS3 expressing model cell lines
system. As shown in Fig. 6A, when T-Rex cells inducibly
expressing full NS3-A4 were supplemented with two tetracycline
concentrations of 1mg/ml or 0.01mg/ml, a considerably lower in-
vivo proteolytic activity was observed in the cells supplemented
with the lower tetracycline concentration. In agreement, less
profound enhancement in cytotoxicity was observed when low
tetracycline concentration supplemented cells where treated with
both DTA and RTA based zymoxins, (Fig. 6B), demonstrating the
expected positive correlation between cellular NS3 proteolytic
activity level and enhancement in zymoxins induced cytotoxicity.
The cytotoxicity of DTA and RTA based zymoxins is
elevated in a hepatoma-derived cell line stably
expressing NS3 protease or infected with HCV
In order to evaluate the potential of the described zymoxins to
be cleaved in the cytoplasm of HCV infected cells, Huh7.5
hepatoma cells uninfected or infected with the 1a/2a chimeric
virus HJ3-5 (encoding the structural proteins of genotype 1a strain
H77S within the background of genotype 2a strain JFH1) [55,56]
Figure 5. Viability assay of NS3 expressing cells treated with RTA based zymoxins. T-Rex cells inducibly expressing scNS3 or full NS3-4A
were seeded (4610
4 cells per well) in 96-well plates. After 9 hours, cells were treated with 1mg/ml of tetracycline (+TET) or left untreated (NO TET).
Two hours later, cells were incubated for 72 hours with serial dilutions of the toxins ‘‘PE-RTA-cleavage site-stalk peptide’’ or ‘‘PE-RTA- mutated
cleavage site-stalk peptide’’ (presence of tetracycline was kept in the growth media of induced cells). The relative fraction of viable cells was
determined using an enzymatic MTT assay. A representative graph of three independent experiments is shown. Each point represents the mean 6SD
of a set of data determined in triplicates.
doi:10.1371/journal.pone.0015916.g005
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(A). In vivo substrate cleavage efficiency analysis: T-Rex cells inducibly expressing full NS3-4A were transfected with 2mg of the vector ‘‘pCMV/MBP-
EGFP-NS5AB-CBD’’. After 24 hours, cells were treated with 1mg/ml of tetracycline, 0.01mg/ml of tetracycline or left untreated. 24 hours later, cells were
lysed and samples of 6mg protein from total cell extract where analyzed by immunoblotting with mouse-serum anti-MBP followed by HRP-
conjugated secondary antibodies and ECL development. (B). Viability assay: T-Rex cells inducibly expressing full NS3-4A were seeded (2610
4 cells per
well) in 96-well plates. After 24 hours, cells were supplemented with 1mg/ml of tetracycline (+TET (1 microgram/ml)), 0.01mg/ml of tetracycline (+TET
(0.01microgram/ml)) or left untreated (NO TET). Eight hours later, cells were incubated for 72 hours with serial dilutions of the toxins ‘‘PE-DTA-
cleavage site-defensin’’ or ‘‘PE-RTA- cleavage site-stalk peptide’’ (toxins were diluted in growth media supplemented with the appropriate tetracycline
concentration. presence of tetracycline was kept in the growth media of induced cells). The relative fraction of viable cells was determined using an
enzymatic MTT assay. Each point represents the mean 6SD of a set of data determined in triplicates.
doi:10.1371/journal.pone.0015916.g006
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vectors. These vectors, named ‘‘pCMV/MBP-EGFP-full 1b
NS5AB-CBD’’ and ‘‘pCMV/MBP-EGFP-full 2a JFH1 NS5AB-
CBD’’, encodes for the previously described NS3 cleavable
substrate, with the following modifications: the 10 amino acid
minimal NS3 cleavage sequence from genotype 1b/1a NS5A/B
junction was replaced by longer cleavage sequences of 18 amino
acids (P10-P89) and 20 amino-acids (P10-P109) from 1b or 2a
(strain JFH1) genotype NS5A/B junction sites, respectively
( longer recognition sequences were demonstrated to be cleaved
more efficiently by NS3 [57]). Western blot analysis of lysate
samples from uninfected and HJ3-5 infected cells indicates the
cleavage of the substrate incorporating the 2a NS5A/B site in
infected cells (in which the NS3 protease encoded by the 2a
genotype component of the chimera is expressed) (Fig. 7A, left
panel). Accordingly, for the following experiments , the 1b/1a
genotype derived NS5A/B minimal cleavage site (P6-P49)w a s
replaced by the longer 2a genotype (strain JFH1) NS5A/B junction
sequence (P10-P109) in both DTA and RTA based cleavable
zymoxins (‘‘PE-DTA-full 2a JFH1 cleavage site-defensin’’ and ‘‘PE-
RTA-full 2a JFH1 cleavage site- stalk peptide’’, respectivelz).
Since HCVcc systems are based on the Huh7.5 hepatoma cell
line, we first evaluated whether NS3 expression within Huh7.5 cells
would render them sensitive to zymoxin intoxication as was
observed for the inducible NS3 expressing HEK293 model cell
lines. To this end, Huh7.5 hepatoma-derived cell line stably and
constitutively expressing the described EGFP-full NS3-4A (from 1a
genotype) was established. These cells were then verified for in-vivo
NS3 proteolytic activity toward the cleavage substrate encoded by
the vector ‘‘pCMV/MBP-EGFP-full 2a JFH1 NS5AB-CBD’’. As
shown in the right panel ofFig.7A, thesubstrate wasindeedcleaved
by the 1a genotype full NS3-A4 protease expressed in these cells. At
the Next step, wild-type and EGFP-full NS3-4A expressing Huh7.5
cells were treated with the cleavable zymoxins ‘‘PE-DTA-full 2a
JFH1 cleavage site-defensin’’ and ‘‘PE-RTA-full 2a JFH1 cleavage
site- stalk peptide’’ , or their uncleavable controls. As shown in
Fig.7B, the uncleavable control toxins showed no NS3-dependent
enhancement in cytotoxicity. In contrast, toxicity of both cleavable
zymoxins was enhanced upon treatment of full NS3-4A expressing
Huh7.5 cells, demonstrating that NS3 expression is sufficient for
sensitizing hepatoma-derived Huh7.5 cells to these toxins and
further emphasizes the potential of these engineered toxins in
eradication of NS3 expressing liver cells.
Next, we turned to evaluate the potential of the described
zymoxins in eradicating HCV infected Huh7.5 cells. As can be
seen in Fig. 8, treatment of infected/uninfected Huh7.5 cells with
both cleavable DTA and RTA based zymoxins resulted in
enhanced cytotoxicity upon infected cells (IC50 values of ,3500
and 200 ng/ml for the DTA based toxin toward uninfected and
infected cells, respectively; and ,2500 and 300 ng/ml for the
RTA based toxin toward uninfected and infected cells, respec-
tively). Treatment with the uncleavable controls resulted in a
much less profound effect (IC50 values of ,40 and 30 ng/ml for
the uncleavable DTA based toxin toward uninfected and infected
cells, respectively, and ,900 and 800 ng/ml for the uncleavable
RTA based toxin toward uninfected and infected cells, respec-
tively). No enhancement in cytotoxicity upon infected cells was
observed following treatment with the DTA-based uncleavable
toxin, ‘‘PE-DTA-no cleavage site- defensin’’, in which the whole
NS3 cleavage site was deleted (data not shown). As expected,
treatment of infected cells with toxins incorporating NS5A/B
cleavage site derived from the 1b genotype (that is inefficiently
cleaved by the 2a genotype encoded protease) yielded much
reduced enhancement in cytotoxicity, if any (data not shown).
Discussion
Until these days, vaccination is considered to be the most
efficient method for fighting viral infections. However, active
vaccination is generally taken as a prevention act and usually when
the patient is still uninfected. Moreover, for some viral pathogens
which cause world-wide health problem like human immunode-
ficiency virus (HIV) and HCV, no efficient vaccine had yet been
developed.
Intensive efforts over the past decade has been focused on the
discovery of anti-viral agents that interfere with specific steps in the
viral life cycle which includes viral entry, RNA translation and
post-translational processing, reverse transcription, genome inte-
gration, viral assembly and release [58,59,60]. The processing of a
polyprotein precursor by a viral-encoded protease is an essential
step in the life cycle of many viruses. A partial list of human
diseases associated viruses encoding protease(s) in their genome
include flaviviruses such as hepatitis C virus (HCV), West Nile
virus (WNV), dengue fever virus (DFV) and yellow fever virus
(YFV); retroviruses such as HIV-1, picornaviruses such as
coxsackievirus, poliovirus and hepatitis A virus , nidoviruses such
as coronaviruses (CoV), including the severe acute respiratory
syndrome (SARS) causative SARS-CoV and herpesviruses such as
varicella-zoster virus (VZV) and Epstein-Bar virus (EBV) [61,62].
It is conceivable that many viruses from that list can be targeted by
the ‘‘zymoxin’’ approach, depending on the intracellular location
and expression/activity levels of their encoded proteases.
Varshavsky suggested an innovative concept for antiviral
therapy based on the idea of taking advantage of a specific viral
activity instead of inhibiting it. The proposed antiviral agents,
which he denoted ‘‘sitoxins’’ (for ‘‘signal-regulated cleavage-
mediated toxins’’), were artificially composed of an intracellular
signaling moiety that inactivates a toxin, e.g. a degradation signal,
which can be cleaved off by a viral protease, resulting in a selective
intoxication of virally infected cells [5]. In later studies, a slightly
different strategy for construction of viral-protease activated agents
was also applied. This strategy was based on a ‘‘zymogenization’’
of a potentially toxic enzyme, namely, converting a constitutively
active enzyme to a protease-activatable form in a way which is not
mediated by an intracellular signaling moiety. Such ‘‘zymogen-
ized’’ agents were presented in three elegant studies in which
Plasmodium falciparum, HIV and HCV protease activated zymogens
were designed by circular permutation of bovine RNase A. the
enzyme was modified to expose its natively structured active site
only upon proteolytic cleavage specifically mediated by the above
proteases, which elicited a profound enhancement in in-vitro
RNase activity [63,64,65]. In another study that was carried out
by Jucovic and colleagues, a random propeptide library was fused
to the C-terminal end of Vip2, an actin modifying vegetative
insecticidal protein (Vip) produced by the spore-forming bacteri-
um Bacillus cereus. By selecting for malfunctional fusion variants in
yeast, they identified a Vip2 proenzyme with significantly reduced
enzymatic activity and with the ability to be expressed as a
transgene in corn plants without causing developmental pathology.
Moreover, the engineered zymogen was still powerful enough to
cause the mortality of western corn rootworm larvae, a major pest
of corn in the United States, due to proteolytic activation in the
rootworm digestive system [66]. Recently, Law et al have
demonstrated the conversion of a natural zymogen, the maize
ribosome inactivating protein (maize RIP), into an HIV protease-
activated toxin [67]. The maize RIP is a type III ribosome-
inactivating protein which in its native form is synthesized as
inactive precursor (pro-RIP) and is activated by proteolytic
removal of a 25 amino-acid inhibitory internal peptide in-planta
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e15916Figure 7. Substrate cleavage efficiency analysis and viability assay of NS3 expressing Huh7.5 cells treated with zymoxins. (A). In vivo
substrate cleavage efficiency analysis. Left panel: Huh7.5 cells uninfected or infected with 1a/2a chimeric virus HJ3-5 were seeded (3610
5 cells per
well) in 6 well plate. After 24 hours, cells were transfected with 2mg of the vector ‘‘pCMV/MBP-EGFP-full 1b NS5AB-CBD’’ or ‘‘pCMV/MBP-EGFP-full 2a
JFH1 NS5AB-CBD’’ incorporating NS3 P10-P89 and P10-P109 cleavage sites from 1b genotype or 2a genotype (strain JFH1) NS5A/B junctions,
respectively. 48 hours post transfection, cells were lysed and samples of 20–60 mg protein from total cell extracts (normalized to contain similar
quantities of total cleavage substrate by evaluation of transfection efficiency using fluorescence microscopy analysis) where analyzed by
immunoblotting with mouse-serum anti-MBP. Right panel: w.t Huh7.5 cells or Huh7.5 cells stably and constitutively expressing EGFP-full NS3-4A were
seeded (3610
5 cells per well) in 6 well plate. After 24 hours, cells were transfected with 2mg of the vector ‘‘pCMV/MBP-EGFP-full 2a JFH1 NS5AB-CBD’’.
48 hours post transfection, cells were lysed and samples of 15 mg protein from total cell extracts where analyzed by immunoblotting with mouse-
serum anti-MBP followed by HRP-conjugated secondary antibodies and ECL development. (B). Viability assay: w.t or EGFP-full NS3-4A expressing
Huh7.5 cells were seeded (1610
4 cells per well) in 96-well plates. After 24 hours, cells were incubated for 96 hours with serial dilutions of the
cleavable toxins ‘‘PE-DTA-full 2a JFH1 cleavage site-defensin’’ and ‘‘PE-RTA-full 2a JFH1 cleavage site- stalk peptide’’, or their uncleavable controls. The
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internal inactivation region with two HIV-protease recognition
sequences, a modified zymogen toxin was prepared which showed
enhanced enzymatic and anti-viral activity (it was demonstrated
that several RIPs possess a potent antiviral activity [70]) in HIV
infected cells [67]. However, no data relating to differences
between the cytotoxicity against uninfected vs. infected cells was
provided; thus the potency of this re-engineered toxin in actual
eradication of HIV infected cells cannot be determined. When
treating retroviral infection, eradication of infected cells has an
important ‘‘added value’’ over inhibition of viral replication and
particle production in living cells. The reason for this is that the
infected cells may contain an integrated proviral DNA in their
genome, which can only be eliminated by destroying the cell itself.
During our zymoxins study described herein, we have tried a
similar approach in order to convert the maize RIP into an HCV
protease-activated toxin. However, in our hands, insertion or
replacement of sequences surrounding the internal inhibitory
Figure 8. Viability assay of HCV infected/uninfected Huh7.5 cells treated with zymoxins. Huh7.5 cells uninfected or infected with HJ3-5
chimeric virus were seeded (1610
4 cells per well) in 96-well plates. After 24 hours, cells were incubated for 96 hours with serial dilutions of the
cleavable toxins ‘‘PE-DTA-full 2a JFH1 cleavage site-defensin’’ and ‘‘PE-RTA-full 2a JFH1 cleavage site- stalk peptide’’, or their uncleavable controls. The
relative fraction of viable cells was determined using an enzymatic MTT assay. A representative graph of three independent experiments is shown.
Each point represents the mean 6SD of a set of data determined in triplicates.
doi:10.1371/journal.pone.0015916.g008
relative fraction of viable cells was determined using an enzymatic MTT assay. Each point represents the mean 6SD of a set of data determined in
triplicates.
doi:10.1371/journal.pone.0015916.g007
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that exhibits significant enhancement in cytotoxicity against NS3
expressing cells (unpublished data).
Integrating the concept of ‘‘sitoxins’’ with the strategy of
enzyme ‘‘zymogenization’’, we have developed two rationally
designed viral-protease activated chimeric toxins, which we
denoted ‘‘zymoxins’’ for ‘‘zymogenized toxins’’. The HCV NS3
protease has been chosen to serve as a model for a virally encoded
protease which expression and activity in infected cells is essential
for viral replication/maturation [22]. In both zymoxins, the
binding and translocation domain of Pseudomonas exotoxin A (PE)
were used as a vehicle for the delivery of NS3 cleavable
‘‘zymogenized’’ catalytic subunits of the diphtheria toxin A (from
Corynebacterium diphtheria) or ricin A (from Ricinus communis) into the
cytosol of mammalian cells [45,52].
In contrast to sitoxins, in which the inhibitory activity is
mediated by intracellular components which recognize a cleavable
signaling polypeptide fused to a toxin; the inhibition of the toxic
activity of the zymoxins is mediated solely by the modification
applied to the original toxin. Therefore, we first confirmed NS3
proteolytic activation of the two zymoxins by in-vitro activity assays.
In order to assay translocation capability and NS3 proteolytic
activation in-vivo, a model HEK293 cell line inducibly expressing
the HCV NS3-protease was established. It was previously reported
that sitoxins that are pre-activated in-vitro by the HIV protease
have increased ability to inhibit cellular protein synthesis.
However, these sitoxins subsequently failed to inhibit the growth
of HIV infected cells, and it was suggested by the authors that this
failure was due to the fact that the HIV virus-encoded protease is
located at the plasma membrane and not available to activate the
sitoxins [6]. Hence, zymoxins activation was assayed using both
cytosolic and membrane-associated NS3 expressing cells as cellular
localization of the protease may influence the probability of
interaction with translocated toxins. The latter model of
membrane associated NS3 expression system was particularly
important since it should more precisely mimic the intracellular
localization of the genuine viral-encoded NS3 protease domain.
Our results show a considerable NS3-dependent enhancement
in cytotoxicity for the two zymoxins in both model cell lines,
leading to specific eradication of protease expressing cells at
specific ranges of zymoxin concentrations. This demonstrates the
competence of the binding and translocation domains of PE to
mediate delivery of the DTA and RTA catalytic domains into cells
cytoplasm and, importantly, that NS3 cleavage mediated en-
hancement in the enzymatic activity of the two zymoxins (as was
detected by in-vitro assays) is practically translated to enhancement
in cytotoxic activity.
In order to test the competence of the zymoxins in eradicating
HCV infected liver cells, we utilized one of the currently used models
to study hepatitis C virus in which recombinant infectious HCV
particles are produced in cell culture (HCVcc) based on Huh7.5
hepatoma cell line [23,24,25,26,27,28,29,30,31,56]. First, we have
verified that NS3 expression sensitizes Huh7.5 liver cells to zymoxin
intoxication as was observed following inducible NS3 expression in
HEK293 cell lines. Finally, we show that treatment with both
c l e a v a b l eD T Aa n dR T Ab a s e dz y m o x i n sr e s u l t e di ne n h a n c e d
cytotoxicity toward HCVinfected Huh7.5 cells.In contrast, when the
cells were treated with uncleavable control toxins, no therapeutic
window was observed. Further support to the authenticity of these
results was provided by our unpublished observations that toxins
incorporating 1b genotype derived HCV NS5A/B site (that is
inefficiently cleaved by the 2a genotype encoded protease in HCV
infected cells) resulted in a minor or undetectable enhancement in
cytotoxicity upon treatment of infected cells.
Of note in the experiments with HCV infected Huh7.5 cells the
‘‘therapeutic windows’’ were up to ,15 fold, which were narrower
than these observed in the case of the NS3 inducibly expressing
HEK293 T-Rex cell line under conditions of full induction. This
value is also smaller than these observed in similar experiments on
NS3 expressing Huh7.5 cells, were therapeutic windows of up to
30 fold were recorded. Apparently, the level of NS3 protease
activity in HCV infected cells is lower than the level in the model
cell lines, which is also evident when comparing the left and right
panels of Fig. 7A.
In conclusion, the design of the two anti-viral agents presented
in this work was inspired by the ‘‘sitoxins’’ concept presented by
Varshavsky and recent work in the field of enzyme engineering.
The ability of these agents to be activated by a viral protease
provides a proof of concept for the feasibility of ‘‘zymogenization’’
of natural toxins by rational design relaying on previous
knowledge on the toxin’s structure, interaction with substrate
and existence of peptidic inhibitors. Although practical use may
require further research and development in order to broaden the
‘‘therapeutic window’’ and reduce potential immunogenicity of
these drugs; eradication of virally infected cells by using
zymogenized toxins may represent another strategy in fighting
viral diseases. Still, the ‘‘zymoxin’’ approach may be most
appropriate for application to life-threatening acute infections
where much higher levels of the activating protease than the ones
observed in HCV infected cells would be expected.
Materials and Methods
Bacterial strains
The following Escherichia coli strains were used: XL-1 Blue
(Stratagene, USA) for plasmid propagation and Rosetta (DE-3)
(Novagen, USA) for expression of the T7 promoter-driven
recombinant toxins.
Recombinant DNA techniques and vectors
Recombinant DNA techniques were carried out according to
standard protocols or as recommended by suppliers. Nucleotide
sequences were determined using the PRISM 3100 Genetic
Analyzer (Applied Biosystems, USA) according to the supplier’s
recommendations. The bacterial T7 promoter-based expression
vector pET28a, used for expression of recombinant toxins in
Escherichia coli, was from Novagen (USA). The eukaryotic
tetracycline-inducible CMV promoter-based expression vector
pcDNA 4/TO, used for expression of EGFP-scNS3 and EGFP-
full NS3-4A in T-REx 293 Cell Line was from Invitrogen (USA).
All plasmid and DNA fragment purifications were carried out with
HiYield Plasmid Mini Kit and HiYield Gel/PCR DNA Extraction
Kit (RBC bioscience, Taiwan). T4 DNA ligase and restriction
enzymes were purchased from New England Biolabs (USA). DNA
ligations were carried out at 16uC overnight.
Plant genomic DNA extraction
Genomic DNA extraction from Ricinus communis was performed
as described in [71].
Construction of NS3 protease expression vectors
Construction of the tetracycline-inducible vector encoding
EGFP-scNS3. the previously described NS4A-NS3 (single-chain
NS3; scNS3) [32,33,34,35] coding sequence was amplified by PCR
using the plasmid ‘‘pMGT14’’ [32] DNA as template, and the
primers 1-cytons3 and 2-cytons3 (primer sequences are given in
supporting Table S1).
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(restriction sites are underlined in the primer sequences) and was
cloned between the corresponding sites in pEGFP-C2 (Clontech,
USA), generating plasmid ‘‘pEGFP C2- scNS3’’. Next, a fragment
containing the coding sequence of the EGFP-scNS3 fusion was
excised from the above plasmid by digestion with Eco47 III and
ApaI and was cloned between the corresponding sites in the
Tetracycline inducible vector pcDNA 4/TO , generating plasmid
‘‘pcDNA 4/TO EGFP-scNS3’’.
Construction of the tetracycline-inducible vector encoding
EGFP- full NS3-4A. The coding sequence of the full length NS3
(including the helicase domain) followed by NS4A from 1a HCV
genotype was excised from the plasmid ‘‘NS3/4A-pVAX1’’ [36],
kindly provided by Prof. Matti Sa ¨llberg, Karolinska University
Hospital, Sweden, by digestion with NarIa n dApaI. The DNA
fragment was then cloned between the corresponding sites in
‘‘pcDNA 4/TO EGFP-scNS3’’ (replacing the scNS3 sequence),
generating plasmid ‘‘pcDNA 4/TO EGFP-Full NS3-4A’’.
Construction of vectors for expression of zymoxins based
on DT
Construction of the vector encoding the ‘‘PE-DTA-cleavage
site-defensin’’ zymoxin (shown schematically in Fig. 2A). The
coding sequence of amino acids 1–605 of Pseudomonasexotoxin A (PE),
including a signal peptide, was amplified by PCR from a plasmid
encoding a PE derivative (PE-QQ delta) kindly provided by Dr. Ira
Pastan, NCI, NIH, Bethesda, MD, USA, in which lysines 590 and
606 where substituted with glutamine residues and lysine 613 was
deleted [72].
In the same amplification process, a DNA sequence encoding for
the 10 amino acid minimal NS3 cleavage sequence (P6-P49)f r o m
HCV NS5A/B site derived from HCV genotype 1b/1a [41] followed
by MfeIs i t e ,PstI site, 6 histidine residues (6xHIS) and the KDEL ER
retrieval signal was introduced to the 39 end of the toxin coding
sequence. The primers that have been used are the forward primer
3-DTAclv; And the reverse primers: (in this order, when the PCR
product of the forward and the first reverse primer used as template
for the reaction with the forward and the second reverse primer, and
so on): 4-DTAclv , 5-DTAclv and 6-DTAclv. The final PCR product
was digested with XbaIa n dEcoRI and was cloned between the
corresponding sites in the bacterial expression plasmid pET28a
generating the plasmid ‘‘pET28a PE QQ delta NS5AB-HIS-
KDEL’’. Next, the human alpha-defensin 1 (HNP1) coding sequence
preceded by a flexible linker of 15 amino acids and followed by a
linker of 4 amino acids, both are rich in glycine and serine, was
inserted between the NS5AB and the 6xHIS of the above plasmid.
This insert was created by PCR using the plasmid ‘‘pET28a PE QQ
delta NS5AB-HIS-KDEL’’ DNA as template, the reverse primer
7-DTAclv; And the forward primers: (in this order, when the PCR
product of the reverse and the first forward primer used as template
for the reaction with the reverse and the second forward primer, and
so on): 8-DTAclv, 9- DTAclv, 10- DTAclv and 11- DTAclv.
The PCR product was digested with PstI and EcoRI and was
cloned between the corresponding sites in the same plasmid that
was used as template, generating the plasmid ‘‘pET28a PE QQ
delta NS5AB-15aa linker-HNP-HIS-KDEL’’. In the next step, a
DNA fragment encoding diphtheria toxin A (kindly provided by
Prof. Nadir Arber, Integrated Cancer Prevention Center, Tel Aviv
Sourasky Medical Center, Israel) was used as template for PCR
amplification of the region encoding amino acids 1–187 of the
mature toxic A domain (without the signal peptide). In the same
amplification process, a DNA sequence encoding the 1b derived
P6-P49 NS5A/B junction was introduced to the 39 end of the toxin
coding sequence. The primers that have been used are 12-
DTAclv and 13- DTAclv.
The PCR product was digested with restriction enzymes AatII
and MfeI and was cloned between the corresponding sites in the
plasmid ‘‘pET28a PE QQ delta NS5AB-15aa linker-HNP-HIS-
KDEL’’ generating the plasmid ‘‘pET28a PE QQ delta -DTA
(1–187)(instead domain III) -NS5AB-15aa linker- HNP-HIS-
KDEL’’ in which the catalytic domain of PE (domain III) was
replaced by amino acids 1–187 of DTA, followed by the NS3
cleavable NS5A/B junction sequence, a flexible linker of 15 amino
acids rich in glycine and serine, the human alpha-defensin 1
(HNP1) coding sequence, a short 4 amino acid linker, 6xHIS and
the KDEL retrieval signal. Protein sequences of the zymoxin
described above, as well as all the zymoxins used in the study can
be found in supporting Text S1.
Construction of the vector encoding the control uncleavable
zymoxin ‘‘PE-DTA-mutated cleavage site- defensin’’ (shown
schematically in Fig. 2A). The minimal NS3 cleavage sequence
(P6-P49) derived from NS5A/B junction of HCV 1b/1a genotype in
the plasmid ‘‘pET28a PE QQ delta -DTA(1–187)(instead domain III)
-NS5AB-15aa linker- HNP-HIS-KDEL’’ was mutated bysubstituting
P1 cysteine to arginine and P49 tyrosine to alanine using the DNA of
plasmid ‘‘pET28a PE QQ delta -DTA(1–187)(instead domain III) -
NS5AB-15aa linker- HNP-HIS-KDEL’’ as template with the
following primers: Forward 14-DTAunc ; and reverse: 15-DTAunc
and 16-DTAunc. The PCR product was digested with AatII and PstI
and was cloned between the corresponding sites in the same plasmid
t h a tw a su s e da st e m p l a t e ,g e n e r a t i n gt h ep l a s m i d‘ ‘ p E T 2 8 aP EQ Q
delta -DTA(1–187)(instead domain III)-mutated NS5AB- 15aa
linker-HNP-HIS-KDEL’’.
Construction of the vector encoding the control DTA based
uncleavable toxin, in which the whole NS3 cleavage site was
deleted (‘‘PE-DTA-no cleavage site- defensin’’). A PCR was
carried out using DNA of plasmid ‘‘pET28a PE QQ delta -DTA
(1–187)(instead domain III) -NS5AB-15aa linker- HNP-HIS-
KDEL’’ as template and the primers 17-DTAnoclv and 18-
DTAnoclv. The PCR product was digested with PstIa n dAatII and
wascloned between the correspondingsitesinthe sameplasmid that
was used as template, generating the plasmid ‘‘pET28a PE QQ
delta -DTA(1–187)(instead domain III)- no cleavage site- 15aa
linker-HNP-HIS-KDEL ’’.
Construction of the vector encoding ‘‘PE-DTA-cleavage
site-defensin’’ zymoxin in which the P6-P49 NS3 cleavage
sequence derived from 1b genotype NS5A/B junction was
replaced by the P10-P109 cleavage sequence derived from 2a
genotype (strain JFH1) NS5A/B junction (‘‘PE-DTA-full 2a
JFH1 cleavage site-defensin’’). A PCR was carried out using
DNA of plasmid ‘‘pET28a PE QQ delta -DTA(1–187)(instead
domain III) -NS5AB-15aa linker- HNP-HIS-KDEL’’ as template,
the reverse primer : 19-DTA2aclv; and the forward primers: 20-
DTA2aclvand21-DTA2aclv. The PCRproductwasdigestedwith
StuI and XhoI and was cloned between the corresponding sites in a
plasmid similar to the one used as template, in which the StuIs i t e
was introduced silently (without changing the protein sequence)
upstream to the 1b derived NS5A/B sequence, generating plasmid
‘‘pET28a PE QQ delta -DTA (1–187) (instead domain III)-full 2a
JFH1 NS5AB-15aa linker–HNP-HIS-KDEL’’.
Construction of vectors for expression of zymoxins based
on RTA
Construction of the vector encoding the RTA based
cleavable zymoxin ‘‘PE-RTA-cleavage site-stalk peptide’’
(shown schematically in Fig. 4A). The coding sequence of the
catalytic domain, ricin toxin A chain (amino acids 1–267) was
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using the primers: 22-RTAclv and 23-RTAclv. The PCR product
was digested with SacII and MfeI and was cloned between the
correspondingsitesofplasmid ‘‘pET28aPEQQdeltaNS5AB-HIS-
KDEL’’, generating the plasmid ‘‘pET28a PE QQ delta (I-II-Ib-
RTA)-HIS-KDEL’’, which served as template for another PCR
using the forward primer: 24-RTAclv; and the reverse primers: 25-
RTAclv, 26- RTAclv, 27- RTAclv and 28- RTAclv. The PCR
product was digested with SacII and PstI, and was cloned between
the corresponding sites in the same plasmid that has been used as
template, generating plasmid ‘‘pET28a PE QQ delta RTA-NS5AB-
short linker-stalk peptide-HIS-KDEL’’ in which two repeats of the
acidic 16 residue peptide corresponding to the conserved C terminus
of the ribosomal stalk proteins (EESEESDDDMGFGLFD) have
been fused to the C terminus of RTA, preceded by the P6-P49 NS3
cleavable NS5A/B junction sequence derived from 1b/1a genotype,
a short linker of Gly-Gly-Gly-Gly-Serand followed by6xHIS and the
KDEL ER retrieval signal.
Construction of the vector encoding the uncleavable
control zymoxin ‘‘PE-RTA- mutated cleavage site-stalk
peptide’’ (shown schematically in Fig. 4A). The minimal
NS3 cleavage sequence (P6-P49) derived from NS5A/B junction of
HCV 1b/1a genotype in the plasmid ‘‘pET28a PE QQ delta
RTA-NS5AB-short linker-stalk peptide-HIS-KDEL’’ was mutated
by substituting P1 cysteine to arginine and P49 tyrosine to alanine
using the DNA of plasmid ‘‘ pET28a PE QQ delta RTA-NS5AB-
short linker-stalk peptide-HIS-KDEL’’ as template and the
primers : 29-RTAunc and 30-RTAunc. The PCR product was
digested with BamHI and EcoRI, and was cloned between the
corresponding sites in the same plasmid that has been used as
template, generating the plasmid ‘‘pET28a PE QQ delta RTA-
mutated NS5AB-short linker-stalk peptide-HIS-KDEL’’.
Construction of the vector encoding ‘‘PE-RTA-cleavage
site-stalk peptide’’ zymoxin in which the P6-P49 NS3
cleavage sequence derived from 1b genotype NS5A/B
junction was replaced by the P10-P109 cleavage sequence
derived from 2a genotype (strain JFH1) NS5A/B junction
(‘‘PE-RTA-full 2a JFH1 cleavage site- stalk peptide’’). A
PCR was carried out using DNA of plasmid ‘‘pET28a PE QQ
delta RTA-NS5AB-short linker-stalk peptide-HIS-KDEL’’ as
template, the reverse primer: 31-RTA2aclv; and the forward
primers: 32- RTA2aclv and 33- RTA2aclv. The PCR product was
digested with BamHI and XhoI and was cloned between the
corresponding sites in the same plasmid that has was as template,
generating the plasmid ‘‘pET28a PE QQ delta RTA-full 2a JFH1
NS5AB-short linker-stalk peptide-HIS-KDEL’’.
Construction of the vectors encoding NS3 cleavable
substrates
Construction of the vector encoding the NS3 cleavable
substrate ‘‘MBP-EGFP-NS5AB-CBD’’ bearing the P6-P49
NS3 cleavage sequence derived from 1b/1a genotype
NS5A/B junction (shown schematically in Fig. 1D). The
EGFP-NS5A/B-CBD coding sequence was excised from the
plasmid ‘‘pYB-44’’ [33] by digestion with NcoI and BamHI, and
ligated into the corresponding sites in the plasmid ‘‘pCMV/
H6myc/Cyto-MBP’’ [73], generating plasmid ‘‘pCMV/MBP-
EGFP-NS5AB-CBD’’.
Construction of the vector encoding the NS3 cleavable
substrate ‘‘MBP-EGFP-full 1b NS5AB-CBD’’ bearing the
P10-P89 NS3 cleavage sequence derived from 1b genotype
NS5A/B junction. A PCR was carried out using DNA of plasmid
‘‘pCMV/MBP-EGFP-NS5AB-CBD’’ as template, the reverse
primer: 34-subful1b; and the forward primers: 35- subful1b and
36- subful1b. The PCR product was digested with NheI and
HindIII and was cloned between the corresponding sites in the
same plasmid that was used as template, generating plasmid
‘‘pCMV/MBP-EGFP-full 1b NS5AB-CBD’’.
Construction of the vector encoding the NS3 cleavable
substrate ‘‘MBP-EGFP- full 2a JFH1 NS5AB-CBD’’ bearing
the P10-P109 NS3 cleavage sequence derived from 2a
genotype (strain JFH1) NS5A/B junction. A PCR was carried
out using DNA of plasmid ‘‘pCMV/MBP-EGFP-NS5AB-CBD’’ as
template, the reverse primer: 37-subful2a; and the forward primers:
38- subful2a and 39-subful2a. The PCR product was digested with
NheI and HindIII and cloned between the corresponding sites in the
same plasmid that was used as template, generating plasmid
‘‘pCMV/MBP-EGFP-full 2a JFH1 NS5AB-CBD’’.
Protein expression and purification
E. coli BL21 Rosetta (DE3) cells were transformed with pET28a
based expression plasmids and grown in 1 liter of LB medium
supplemented with 50 mg/ml Kanamycin, at 37uC 250 rpm
shaking to O.D.600nm of 0.8. The cells were chilled down to
30uC and induced with 1mM IPTG for 3–4 hours at 30uC,
250 rpm. The cells were collected by centrifugation at 5000g, at
4uC for 10 minutes. For preparation of periplasmic fractions, the
cell pellet was gently re-suspended in 200 ml of ice-cold 20%
sucrose, 30mM Tris-HCl (pH 7.4), 1mM EDTA, using glass
beads. The cell suspension was incubated on ice for 15 minutes
and centrifuged at 6000g, at 4uC for 15 minutes. The cell pellet
was gently re-suspended in 200 ml of ice cold sterile double
distilled water (DDW), incubated on ice for 15 minutes and
centrifuged at 8000g, 4uC 20 minutes. The supernatant periplas-
mic fraction was adjusted to 20mM Tris-HCl (pH 8.0), 300mM
NaCl and 5mM Imidazole. The periplasmic fraction was
incubated over-night, in continues rotation with 350ml of Ni-
NTA resin (Favorgen, Taiwan) that was previously equilibrated
with binding buffer (20mM Tris-HCl pH 8.0, 300mM NaCl). Ni-
NTA resin was then separated from the periplasmic supernatant
by 5 minutes centrifugation at 70g, 4uC, loaded on Poly Prep
column (Bio-Rad, USA) and washed with 20ml of binding buffer
+5mM imidazole. Bound His-tagged protein was subsequently
eluted with 700ml PBS containing 500mM imidazole, and dialyzed
twice against 1 liter of PBS.
Cell culture, transfection, protein extraction and
immunoblotting
Human embryonic kidney cells HEK293, stably expressing the
tetracycline repressor protein (T-REx 293 Cell Line, Invitrogen,
USA), and human hepatoma cells Huh7.5 [31] were used
throughout this study. Cell lines were maintained in DMEM
supplemented with 10% fetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and
12.5 U/ml nystatin (Biological Industries, Israel) in a humidified
5% CO2 incubator at 37uC.
The calcium-phosphate transfection method was applied for
introducing 2mg of the plasmids ‘‘pcDNA 4/TO EGFP-scNS3’’,
‘‘pcDNA 4/TO EGFP-Full NS3-4A’’ or ‘‘pCMV/MBP-EGFP-
NS5AB-CBD’’ into T-Rex 293 cells, seeded 1.5610
6 cells per 6cm
plate 24 hours before transfection. Stable transfectants, inducibly
expressing EGFP-scNS3 or EGFP-Full NS3-4A were selected in a
medium containing zeocin (100mg/ml and 50mg/ml for selection
and maintenance, respectively) (CAYLA, France).
2mg of the plasmids ‘‘pCMV MBP-EGFP-full 1b NS5AB-
CBD’’, ‘‘pCMV MBP-EGFP-full 2a JFH1 NS5AB-CBD’’ or
‘‘pcDNA 4/TO EGFP-Full NS3-4A’’ were introduced into
uninfected or HCV infected Huh7.5 Cells (seeded 3610
5 cells
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FuGENE 6 reagent (Roche, Germany), according to the
manufacturer instructions. Stable transfectants, constitutively
expressing EGFP-Full NS3-4A were selected and maintained in
a medium containing zeocin (100mg/ml and 5mg/ml for selection
and maintenance, respectively).
For protein extraction, 48 hours post-transfection the cells were
washed with PBS, scraped and lysed in a buffer containing
150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 10 mM Tris(HCl)
pH 7.5, and protease inhibitors cocktail (Sigma, Israel). Following
30 minutes of incubation on ice, lysates were cleared by
centrifugation at 20,000 g for 10 minutes, at 4uC. For immuno-
blotting, protein samples were electrophoresed on 12% SDS/
polyacrylamide gel, transferred to nitrocellulose and detected using
rabbit polyclonal anti-GFP antibody (Santa-Cruz, USA) or
polyclonal mouse serum anti-MBP followed by HRP-conjugated
goat anti-rabbit or anti-mouse mouse antibodies (Jackson Im-
munoResearch Laboratories, USA) and ECL detection. Immuno-
blotting of purified recombinant toxins was similarly performed,
using rabbit polyclonal anti-PE antibody, kindly provided by Dr.
Ira Pastan, NCI, NIH, Bethesda, MD, USA.
Viral infection
Virus assays were carried out with an inter-genotypic chimeric
virus produced by replacing the core-NS2 segment of the JFH-1
virus genome with the comparable segment of the genotype 1a
H77 virus. This chimeric virus, HJ3-5 (Kindly provided by Prof.
Stanley Lemon, University of Texas at Galveston), contains two
compensatory mutations that promote its growth in cell culture as
described previously [55,56]. HCV RNAs were transcribed in vitro
and electroporated into cells essentially as described previously
[74,75]. In brief, 10 mgo fin vitro-synthesized HCV RNA was
mixed with 5610
6 Huh7.5 cells in a 2-mm cuvette and pulsed
twice at 1.4 kV and 25 mF. Cells were seeded into 12-well plates or
25-cm
2 flasks, and passaged at 3-to 4-day intervals posttransfection
by trypsinization and reseeding with a 1:3 to 1:4 split into fresh
culture vessels. When infectivity reached .90%, as was monitored
by immunofluorescent staining with anti HCV core protein, cells
were taken for cytotoxicity or substrate cleavage assays.
Immunofluorescence Microscopy
1610
5 T-REx 293 cells inducibly expressing EGFP-scNS3 or
EGFP-full NS3-4A were seeded on poly-L-lysine coated cover-slips
in a 24 well-plate. After 12 hours, the cells were treated with 1mg/
ml of tetracycline for 24 hours (or remained untreated), washed
with PBS, fixed with 4% paraformaldehyde in PBS at room
temperature for 20 minutes, permeabilized with Triton X-100
(0.1% in PBS) for 5 minutes, and blocked with 90% fetal calf
serum/10% PBS at room temperature for 25 minutes. Slides were
incubated with 1:200 diluted rabbit-polyclonal anti-calnexin
antibody (Sigma, USA) as primary antibody for 1 hour, and
followed by 1:500 diluted Cy3-conjugated anti-rabbit IgG (Jackson
ImmunoResearch Laboratories, USA) secondary antibody and
Hoechst 33258 (5mg/ml) (Sigma, USA) for 1 hour at room
temperature. Slides were washed with PBS, mounted in ImmuGlo
Mounting Medium (IMMCO Diagnostics, USA), and examined
with a Zeiss LSM 510 META laser scanning confocal microscope.
For infectivity assays, Huh7.5 cells infected with HCV HJ3-5
chimeric virus were seeded into 8-well chamber slides (Nalge Nunc,
USA).After24 hours,cellswerefixedandpermeabilizedasdescribed
above and stained with 1:300 diluted mouse monoclonal antibody
C7-50 (Affinity BioReagents, USA) specific for the HCV coreprotein
followed by staining with 1:100 diluted Cy2-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories, USA). Slides
were mounted and examined using a fluorescence microscope.
In-vitro cleavage of DTA and RTA based toxins
600ng of DTA based toxins or 3000ng of RTA based toxins
were incubated with or without 500ng or 1000ng, respectively, of
recombinant MBP-scNS3 fusion [32] in a reaction buffer (50mM
Tris-HCl (pH 7.5), 150mM NaCl, 0.05% tween 20, 20% glycerol
and 1.7mM of DTT) in a total volume of 60ml for 1 hour at 37uC.
NS3 mediated cleavage was verified by western blotting of 50ng
(DTA based toxins) or 250ng (RTA based toxins) toxin samples
using rabbit polyclonal anti-PE antibody as described above.
ADP-ribosylation assay
The ADP-ribosylation activity of DTA based toxins was
determined by measuring transfer of ADP-ribose from
[
14C]NAD to EF-2 essentially as described at [76]. Shortly, 30ng
of each toxin were diluted to 210mL in 50mM Tris-HCl (pH 8.0),
1 mM EDTA, and 0.1% BSA. Mixture was incubated with wheat
germ extract in the presence of 2.4 mM[
14C] NAD (6610
5 cpm)
(Amersham Biosciences, UK) for 40 minutes at RT. Reactions
were terminated by addition of TCA to the reaction mixture
which resulted in total protein precipitation. Level of ADP-
ribosylated EF2 was assessed by measuring the radioactivity of the
precipitated protein by a scintillation counter.
Ribosome depurination assay
The catalytic activity of ricin A based toxins was determined by
a modification of the in-vitro assay described at [53,54]. A serial
dilutions of the cleavable or uncleavable RTA based toxins
(treated or untreated with NS3) were incubated with 10mlo f
micrococcal nuclease-treated rabbit reticulocyte lysate (Promega,
USA) for 30 minutes at 30uC, after which total RNA from each
mixture was extracted with phenol and chloroform, precipitated in
ethanol and suspended in 22ml of water. Half of the RNA (11ml)
was then treated with 50ml of acidic aniline (1M aniline in 2.8 M
acetic acid) for 10 minutes at 40uC and the other half remained
untreated. Next, RNA was recovered by precipitation with
ammonium acetate and ethanol, and analyzed by 3% TBE
agarose gel electrophoresis.
Cell-viability assay
The Cell-killing activities of recombinant toxins were measured
by a MTT assay. For cytotoxicity assay on T-REx 293 cells
inducibly expressing NS3 protease: 4610
4 or 2610
4 cells were
seeded per well in 96-well plates. After 9 or 24 hours, respectively,
cells were treated with indicated concentration of tetracycline or
left untreated. 2 or 8 hours later, respectively, cells were incubated
with serial dilutions of the toxins (presence of tetracycline was kept
in the growth media of induced cells). After 72 hours, the media
was replaced by fresh media (100 ml per well) containing 1 mg/ml
MTT (Thiazolyl Blue Tetrazoliam Bromide (Sigma, USA)
dissolved in PBS) reagent and the cells were incubated for another
30 minutes. MTT-formazan crystals were dissolved by the
addition of extraction solution (20% SDS, 50% DMF, pH 4.7)
(100 ml per well) and incubation for 16 hours at 37uC. Absorbance
at 570 nm was recorded on an automated microtiter plate reader.
The results were expressed as percentage of living cells relatively to
the untreated controls. The IC50 value is the concentration of the
toxin which inhibited cell growth by 50%.
For cytotoxicity assay on HCV infected or uninfected HUH7.5
cells or NS3 expressing Huh7.5 cells: 1610
4 Huh7.5 cells
uninfected or infected with HJ3-5 chimeric virus or stably
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After 24 hours, cells were incubated with serial dilutions of the
toxins. 96 hours later, the media was replaced by fresh media
(100 ml per well) containing 1 mg/ml MTT and the cells were
incubated for another 60 minutes. Further steps were identical to
theses described above.
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